You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK):一季度產品收入共計1.061億美元
格隆匯 05-07 08:19

格隆匯 5 月 7日丨百濟神州(06160.HK)發佈公吿,2021年5月7日,百濟神州公佈近期業務亮點、預計里程碑事件以及2021年第一季度財務業績。2021年第一季度產品收入共計1.061億美元;相比較,去年同期為0.521億美元。自新版國家醫保藥品目錄2021年3月正式執行以來,百澤安®百悦澤®和安加維®的市場需求顯著增加。與諾華就百澤安®達成的合作與授權協定正式生效且由此獲得6.5億美元預付款。此外,廣州生物藥生產基地於3月獲准商業化生產,進一步提升百澤安®在中國的市場供應以及公司總體戰略能力

百濟神州創始人、首席執行官兼董事長歐雷強(John V. Oyler)先生表示:“2021 年第一季度,公司在多項關鍵戰略目標中取得長足進展,包括在中國擴大商業發展規模,在全球範圍內遞交多項上市註冊申請以改善藥物可及性,繼續推進涵蓋潛在同類第一和自主研發組合用藥在內的產品管線,以及進一步提高生物藥生產能力。自3月1日新版國家醫保藥品目錄正式執行以來,公司三款納入醫保目錄的創新抗腫瘤藥物以及商業化產品線的市場表現令人振奮。此外,公司與諾華達成的授權與合作協定正式生效,也由此獲得一筆高達6.5億美元的預付款。不久前,我們還宣佈了在針對慢性淋巴細胞白血病的ALPINE 3期臨牀試驗的中期分析中,取得了積極結果,進一步展現出百悦澤®的差異化及其成為同類最優藥物的潛力。我們相信百濟神州能夠履行創立之初的使命-為全球數十億人口提供高質量的藥物。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account